Based on breast cancer data sets in the TMNplot and GOBO databases, we confirmed that PDIA3 expression is elevated in invasive breast tumors and correlated with the clinical outcome of DMFS time for several breast cancer subtypes, confirming its relevance as potential new target. This evidence concerns the gene PDIA3 and breast carcinoma.